메뉴 건너뛰기




Volumn 51, Issue 2, 2003, Pages 213-217

Stopping HIV fusion with enfuvirtide: The first step to extracellular HAART

Author keywords

Fusion inhibitor; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GROWTH HORMONE; INTERLEUKIN 2; NUCLEOSIDE DERIVATIVE; T 1249; T LYMPHOCYTE RECEPTOR;

EID: 0037323819     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg066     Document Type: Article
Times cited : (36)

References (14)
  • 1
    • 0037192551 scopus 로고    scopus 로고
    • Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial
    • Meynard, J. L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G. et al. (2000). Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16, 727-36.
    • (2000) AIDS , vol.16 , pp. 727-736
    • Meynard, J.L.1    Vray, M.2    Morand-Joubert, L.3    Race, E.4    Descamps, D.5    Peytavin, G.6
  • 2
    • 0033606540 scopus 로고    scopus 로고
    • Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
    • Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P. et al. (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353, 2195-9.
    • (1999) Lancet , vol.353 , pp. 2195-2199
    • Durant, J.1    Clevenbergh, P.2    Halfon, P.3    Delgiudice, P.4    Porsin, S.5    Simonet, P.6
  • 3
    • 0033920318 scopus 로고    scopus 로고
    • A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
    • CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS
    • Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A. et al. (2000). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 14, F83-93.
    • (2000) AIDS , vol.14
    • Baxter, J.D.1    Mayers, D.L.2    Wentworth, D.N.3    Neaton, J.D.4    Hoover, M.L.5    Winters, M.A.6
  • 4
    • 0037040360 scopus 로고    scopus 로고
    • A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    • Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S. et al. (2000). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16, 579-88.
    • (2000) AIDS , vol.16 , pp. 579-588
    • Cohen, C.J.1    Hunt, S.2    Sension, M.3    Farthing, C.4    Conant, M.5    Jacobson, S.6
  • 5
    • 0037169170 scopus 로고    scopus 로고
    • Clinical utility of HIV-1 genotyping and expert advice: The Havana trial
    • Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J. et al. (2000). Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16, 209-18.
    • (2000) AIDS , vol.16 , pp. 209-218
    • Tural, C.1    Ruiz, L.2    Holtzer, C.3    Schapiro, J.4    Viciana, P.5    Gonzalez, J.6
  • 6
    • 0033862761 scopus 로고    scopus 로고
    • Clinical manifestations and management of antiretroviral nucleoside analogue related mitochondrial toxicity
    • Moyle, G. (2000). Clinical manifestations and management of antiretroviral nucleoside analogue related mitochondrial toxicity. Clinical Therapeutics 22, 911-36.
    • (2000) Clinical Therapeutics , vol.22 , pp. 911-936
    • Moyle, G.1
  • 7
    • 0036066762 scopus 로고    scopus 로고
    • The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
    • Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C. et al. (2002). The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Pesearch and Human Retroviruses 18, 685-93.
    • (2002) AIDS Pesearch and Human Retroviruses , vol.18 , pp. 685-693
    • Kilby, J.M.1    Lalezari, J.P.2    Eron, J.J.3    Carlson, M.4    Cohen, C.5    Arduino, R.C.6
  • 8
    • 0037471311 scopus 로고    scopus 로고
    • A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide (T-20) based antiretroviral therapy
    • in press
    • Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., DeJesus, E., Arduino, R. C. et al. (2003). A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide (T-20) based antiretroviral therapy. AIDS, in press.
    • (2003) AIDS
    • Lalezari, J.P.1    Eron, J.J.2    Carlson, M.3    Cohen, C.4    DeJesus, E.5    Arduino, R.C.6
  • 9
    • 0013425084 scopus 로고    scopus 로고
    • A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating three doses of T-20 in P1-experienced, NNRTI-naïve patients infected with HIV-1
    • Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 418-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Lalezari, J., DeJesus, E., Northfelt, D., Richmond, G., Delehanty, J., DeMasi, R. et al. (2002). A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating three doses of T-20 in P1-experienced, NNRTI-naïve patients infected with HIV-1. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 418-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2002)
    • Lalezari, J.1    DeJesus, E.2    Northfelt, D.3    Richmond, G.4    Delehanty, J.5    DeMasi, R.6
  • 10
    • 0013382197 scopus 로고    scopus 로고
    • 48-week assessment of high strength T-20 in multi-class experienced patients
    • Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 417-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Wheat, L. J., Lalezari, J., Kilby, M., Wheeler, D., Salgo, M., DeMasi, R. et al. (2002). 48-week assessment of high strength T-20 in multi-class experienced patients. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 417-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2002)
    • Wheat, L.J.1    Lalezari, J.2    Kilby, M.3    Wheeler, D.4    Salgo, M.5    DeMasi, R.6
  • 11
    • 0003209749 scopus 로고    scopus 로고
    • Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in North America and Brazil (TORO 1)
    • Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19B. IAS International AIDS Society, Stockholm, Sweden
    • Henry, K., Lalezari, J., O'Hearn, M., Trottier, B., Montaner, J., Piliero, P. et al. (2002). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in North America and Brazil (TORO 1). In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19B. IAS International AIDS Society, Stockholm, Sweden.
    • (2002)
    • Henry, K.1    Lalezari, J.2    O'Hearn, M.3    Trottier, B.4    Montaner, J.5    Piliero, P.6
  • 12
    • 0003245253 scopus 로고    scopus 로고
    • Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in Europe and Australia (TORO 2)
    • Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19A. IAS International AIDS Society, Stockholm, Sweden
    • Clotet, B., Lazzarin, A., Cooper, D., Reynes, J., Arasteh, K., Nelson, M. et al. (2002). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in Europe and Australia (TORO 2). In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19A. IAS International AIDS Society, Stockholm, Sweden.
    • (2002)
    • Clotet, B.1    Lazzarin, A.2    Cooper, D.3    Reynes, J.4    Arasteh, K.5    Nelson, M.6
  • 13
    • 0013428074 scopus 로고    scopus 로고
    • Patient survey on injection of enfuvirtide (T-20): Ease of use and impact on activities
    • Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuPeB4480. IAS International AIDS Society, Stockholm, Sweden
    • Green, J., Salgo, M. P. & Delehanty, J. (2002). Patient survey on injection of enfuvirtide (T-20): ease of use and impact on activities. In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuPeB4480. IAS International AIDS Society, Stockholm, Sweden.
    • (2002)
    • Green, J.1    Salgo, M.P.2    Delehanty, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.